Study: Drug-Resistant Cancer Cleverer Than Imagined
offers hope after a life-changing cancer diagnosis. But some cancers that initially respond to targeted chemotherapy become treatment-resistant ā and the tumor itself is the culprit.
Now, from Ā鶹ĪŽĀė°ę and UC Irvine is helping explain how therapy-resistant cancers arise ā findings with important implications for the future of cancer therapy. The results are reported in a study
To understand how cancer becomes treatment resistant, a research team at the , led by Ā鶹ĪŽĀė°ę Professor of the School of Natural Sciences, compared genetic and metabolic pathways in treatment-responsive and treatment-resistant melanomas.
is a cancer that originates in melanocytes, the cells that produce the skin pigment melanin. Though not the most common form of skin cancer, it is the most aggressive. And if itās not caught and treated early, itās also among the deadliest.
āMelanoma is usually induced by the sun ā by UV damage,ā Filipp said. āIn the majority of cases, that UV damage changes a single target by causing point mutations.ā
UV damage gives rise to point mutations ā changes in a single letter of the 3 billion letter human genome. These mutations can that tell cells when to grow and divide and when to stop. , the main focus of the new study, cause growth signals to be stuck in the āonā position and drive cancer development.
Ģż
Though scientists have managed to come up with drugs that target and turn off aberrant BRAF signaling, cancer cells are clever and learn to adapt to these BRAF-inhibitors.
āToday, many patients respond to cancer treatment very positively at first,ā Filipp said. āUnfortunately, many ultimately develop resistance and metastases.ā
Though chemotherapy might kill most of the cancer, tiny populations of drug-resistant cancer cells can survive and propagate. Unlike the more familiar case of antibiotic-resistant bacteria, where genetic mutations give rise to resistance, Filipp and his team found that many adaptations in treatment-resistant cancers arenāt the result of mutation.
āCancer is a genomic disease. However, resistance to therapy might go beyond just cancer mutations,ā Filipp explained. āSurprisingly, it was not new mutations that are causing resistance. The DNA stays the same, but cancer cells quickly adapt non-genomically to therapy and outsmart the drugs.ā
Melanoma circumvents BRAF inhibitors not by changing the genes themselves, but by changing gene activity. Filipp and his team found that in treatment-resistant cancers, key regulatory genes were more active while important protective genes were less active when compared with treatment-responsive cancers.
Some of the genes with reduced activity were in the same signaling pathway as BRAF, the mutated protein that gave rise to the cancer and the main target of chemotherapy. Meanwhile, genes with increased activity were in metabolic pathways that allowed cancer cells to bypass BRAF altogether and continue to grow and divide. Cancer cells had essentially figured out how to survive by rewiring their in response to chemotherapy.
Daunting as this may sound, it actually offers hope to scientists and clinicians who want to treat chemo-resistant cancers.
āAfter this study, we now understand how some cancer drugs become ineffective,ā Filipp said. āThis suggests new ways of approaching therapy by looking at pathways and taking advantage of pathways in the and .ā
Itās a discovery that was made thanks in large part to contributions from students in Filippās lab.
āThe work would have not been possible without an incredible team,ā Filipp said. āMany graduate and undergraduate researchers contributed to the project ā which was a collaborative effort between Ā鶹ĪŽĀė°ę and the Cancer Center at UC Irvine.ā
Efforts like this helped Ā鶹ĪŽĀė°ęās graduate science programs , said Dean of Natural Sciences Betsy Dumont.
āGroundbreaking research ā like this new study from Professor Filippās lab, which may one day lead to new therapies for drug-resistant cancers ā is why Ā鶹ĪŽĀė°ę is now counted among the nationās top graduate programs in biology,ā she said.
Filipp is the recipient of the and part of a cancer research cluster at the . Director of the Health Sciences Research Institute Professor Paul Brown, explained how Filippās interdisciplinary approach to cancer research provides a new path forward for tackling the disease.
āThe research combines and uses state-of-the-art computational to identify ways to overcome cancer resistance.ā Brown said. āProfessor Filippās research demonstrates the advantages of taking a multi-disciplinary approach to research. The research is an important contribution to the treatment, control and prevention of cancer.ā
In addition to breakthroughs in cancer research, Filipp is dedicated to promoting advanced graduate training and student mentoring. Filipp has developed cutting-edge training courses on cancer systems biology and is today hosting an focused on metabolic engineering. The symposium features lectures by scientists from the U.S., Germany and Norway, strengthening bridges between American and European researchers.
āThis is a great opportunity for early-career scientists to get involved into ongoing research at Ā鶹ĪŽĀė°ę,ā Filipp said.
